Verona Pharma plc announced that Mr. James Brady has joined the board as a Non-Executive Director. Most recently, Mr. Brady served as Chief Financial Officer of MedImmune, the biologics discovery and development division of AstraZeneca. During his tenure at MedImmune, biologics grew to represent more than half of the product development portfolio of AstraZeneca and five biologics were successfully brought to market.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.95 USD | +0.50% | -5.95% | -30.03% |
May. 13 | HC Wainwright Adjusts Price Target on Verona Pharma to $30 From $32, Maintains Buy Rating | MT |
May. 09 | Verona Pharma Signs Financing Agreements for Up to $650 Million | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.03% | 1.12B | |
+4.24% | 111B | |
+11.47% | 105B | |
-12.98% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.29% | 16.96B | |
+3.36% | 13.7B | |
+37.14% | 12.45B |
- Stock Market
- Equities
- VRNA Stock
- News Verona Pharma plc
- Verona Pharma plc Announces Appointment of James Brad as Non-Executive Director